Novo Holdings’ Principal Investments Provides Update on a Record Year

  • Deployed close to EUR 1.9 billion of equity*
  • Expanded portfolio to 18 companies, including new investments in Altasciences, BBI, Availity, Esco LifeSciences Group, Medical Knowledge Group and The Ritedose Corporation*
  • Increased the Principal Investments’ portfolio value by more than 30% to excess of EUR 10 billion*
  • Three successful (partial) exits
  • Continued team expansion and established direct presence in the US with opening of Boston office

Copenhagen, Denmark, 29 March 2022 – Principal Investments, the arm of Novo Holdings that invests in leading, well-established, growth-oriented healthcare & life science companies, today publishes its annual newsletter.

Read more…